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Abstract
Background: Cardiomyocyte hypertrophy is associated with changes in gene expression. Extracellular signal-regulated
kinases 1/2 (ERK1/2) and RhoA [activated by hypertrophic agonists (e.g. endothelin-1)] regulate gene expression and are
implicated in the response, but their relative significance in regulating the cardiomyocyte transcriptome is unknown. Our
aim was to establish the significance of ERK1/2 and/or RhoA in the early cardiomyocyte transcriptomic response to
endothelin-1.
Methods/Principal Findings: Cardiomyocytes were exposed to endothelin-1 (1 h) with/without PD184352 (to inhibit ERK1/
2) or C3 transferase (C3T, to inhibit RhoA). RNA expression was analyzed using microarrays and qPCR. ERK1/2 signaling
positively regulated ,65% of the early gene expression response to ET-1 with a small (,2%) negative effect, whereas RhoA
signaling positively regulated ,10% of the early gene expression response to ET-1 with a greater (,14%) negative
contribution. Of RNAs non-responsive to endothelin-1, 66 or 448 were regulated by PD184352 or C3T, respectively,
indicating that RhoA had a more significant effect on baseline RNA expression. mRNAs upregulated by endothelin-1
encoded a number of receptor ligands (e.g. Ereg, Areg, Hbegf) and transcription factors (e.g. Abra/Srf) that potentially
propagate the response.
Conclusions/Significance: ERK1/2 dominates over RhoA in the early transcriptomic response to endothelin-1. RhoA plays a
major role in maintaining baseline RNA expression but, with upregulation of Abra/Srf by endothelin-1, RhoA may regulate
changes in RNA expression over longer times. Our data identify ERK1/2 as a more significant node than RhoA in regulating
the early stages of cardiomyocyte hypertrophy.
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Introduction
Cardiomyocytes are the contractile cells of the heart, constitut-
ing ,70% of the volume and ,30% of the total cell number.
Mammalian cardiomyocytes become terminally-differentiated
during the early post-natal period and individual cells grow as
the organism grows, a process that may be defined as ‘‘eutrophy’’
[1]. Cardiomyocytes also undergo hypertrophic growth, defined as
an increase in cardiomyocyte size above that which occurs at any
given stage of post-natal mammalian growth [1,2]. In vivo,
cardiomyocyte hypertrophy is an important adaptational response
that allows the heart to maintain an adequate cardiac output with
improved cardiac contractility in a variety of physiological loading
conditions including pregnancy [3] or endurance exercise such as
voluntary running [4]. This is probably beneficial and is reversible.
In ‘pathological’ conditions (e.g. hypertension or following
myocardial infarction), the heart may initially undergo a
physiological type of hypertrophy in order to increase or maintain
cardiac output. However, this may degenerate possibly because of
ancillary changes (e.g. fibrosis, reduced contractile performance
and chamber dilatation/wall thinning) leading to ‘‘maladaptive’’
hypertrophy and, potentially, heart failure [5].
Cardiomyocyte hypertrophy is associated with morphological
changes (increase in cell size and contractile apparatus) that are
facilitated by changes in gene expression and an increase in the
rate of protein synthesis [1,2]. Changes in gene expression include
re-expression of genes expressed early in development, the so-
called ‘‘fetal’’ programme (e.g. atrial and B-type natriuretic factors,
b-myosin heavy chain), expression of immediate early genes (IEGs)
such as c-jun,c - fos and c-myc, and changes in expression of proteins
associated with contractility [6]. It is assumed that extracellular
stimuli activate a programme of intracellular signaling events that
leads to the changes in gene expression, increased protein synthesis
and the development of a hypertrophic response. Gq protein-
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are particularly implicated in promoting hypertrophy [7]. In
cardiomyocytes, ET-1 potently activates protein kinase C isoforms,
the small G protein Ras and signaling through extracellular signal-
regulated kinases 1/2 (ERK1/2) [7]. ET-1 activates other
mitogen-activated protein kinases (MAPKs), c-Jun N-terminal
kinases (JNKs) and p38-MAPKs, although these are activated
more potently by cellular stresses. Rho-family small G proteins
(RhoA, Rac1) are also activated by ET-1 and other GqPCR
agonists [8]. All these signaling pathways are implicated in
cardiomyocyte hypertrophy [6,8].
Although much is known of the signaling pathways activated
by hypertrophic stimuli, less is known of the genes they regulate.
MAPKs phosphorylate transcription factors (TFs) to modulate
their transactivating activities and regulate IEG expression (e.g.
ERK1/2 phosphorylate and activate Elk1 [6]). IEGs encode
‘‘structural’’ proteins that directly influence cell function and
‘‘regulatory’’ proteins. The latter include TFs that regulate
downstream gene expression and soluble mediators that act in
autocrine/paracrine loops to initiate further cycles of intracel-
lular signaling. RhoA is also particularly implicated in
regulating cardiomyocyte gene expression. Stimulation of actin
‘‘treadmilling’’ by RhoA leads to activation of Abra (also known
as STARS or MS-1) that promotes nuclear translocation
of myocardin-related TFs (MRTFs) [9]. Like Elk1, MRTFs
co-operate with serum-response factor (Srf) to promote
gene expression [6,9]. Precisely which genes are regulated by
these individual signaling pathways and TFs remains to be
established.
We previously mapped the acute, temporal changes in RNA
expression induced in cardiomyocytes by ET-1 [10]. A large
proportion of the very early changes in IEG expression (30 min)
require ERK1/2 or ERK5 signaling (we used U0126 that inhibits
the upstream kinases for both pathways [11]), and this is reflected
in second-phase gene expression (2–4 h) [10,12]. However, the
majority of the IEG response occurs at ,1 h [10] and the relative
contribution of ERK1/2, RhoA or other signaling pathways is
unknown. Here, we used an inhibitor approach to establish the
significance of ERK1/2 vs RhoA in regulating the baseline and
ET-1-responsive cardiomyocyte transcriptome. PD184352 is
highly specific for the ERK1/2 cascade when used at 2 mM
[11] and C3 transferase (C3T) from Clostridium botulinum
inactivates only RhoA/B/C family proteins [13]. We conclude
that, whereas RhoA signaling is significant in maintaining
baseline RNA expression, ERK1/2 signaling is dominant in the
acute response to ET-1 and plays a generally positive role in
RNA expression.
Results
PD184352 (2 mM) inhibited baseline ERK1/2 activity and the
increase induced by ET-1 (Fig. 1A). There was no effect of
PD184352 on baseline activities of p38-MAPKs or JNKs, or on
the increase induced by ET-1 (Fig. 1B). PD184352 alone had no
overt effect on cardiomyocyte morphology as determined by
immunostaining for troponin T (i.e. myofibrillar structure), but
caused some reduction in the increase in myofibrillar organisation
induced by ET-1 (Fig. 1C). C3T (1 mg/ml) inhibited baseline
RhoA.GTP and the activation of RhoA by ET-1 (Fig. 2A). At
5 mg/ml, C3T promoted a further reduction in RhoA.GTP and
reduced the rate of migration through polyacrylamide gels. C3T
(1 mg/ml) had no effect on basal MAPK activities or on activation
of MAPKs by ET-1 (Fig. 2B). Although we detected RhoB.GTP
and RhoC.GTP in cardiomyocyte extracts, we did not detect any
increase in response to ET-1 and C3T had no effect on basal
levels in the affinity purification assay (Fig. 2C). The effects of
C3T on cardiomyocyte RNA expression may therefore be
presumed to be mediated through RhoA. Although RhoA
modulates actin structures, 1 mg/ml C3T had no overt effects
on cardiomyocyte myofibrillar structure or on the increase in
myofibrillar organisation induced by ET-1 (Fig. 2D). However,
5 mg/ml C3T caused some reduction in myofibrillar content with
disruption of myofibrillar structure both in the basal state and
following treatment with ET-1. 1 mg/ml C3T was used for all
further experiments given that this was sufficient to inhibit
RhoA.GTP in the absence of further modification of the protein
(as indicated by reduced gel mobility) or disruption of
cardiomyocyte structure.
To determine the significance of ERK1/2 signaling vs RhoA
signaling in regulating cardiomyocyte RNA expression, cardio-
myocytes were exposed to C3T, PD184352 or ET-1 (1 h) alone, or
C3T or PD184352 with ET-1. Transcriptional profiling was
performed with Affymetrix Rat Genome 230 2.0 microarrays
using GeneSpring for analysis. Of 16285 probesets detecting
RNAs in cardiomyocytes, 1323 were significantly changed in any
condition (PD184352, C3T, ET-1, PD184352/ET-1, C3T/ET-1)
relative to controls (.1.5-fold change; false discovery rate,
FDR,0.05). These were clustered according to ET-1 response
and the effects of PD184352 (Fig. 3) or C3T (Fig. 4).
Of 273 RNAs upregulated by ET-1, 83 were unaffected by
PD184352, whereas upregulation of 184 or 6 was either inhibited
or enhanced, respectively (Fig. 3A, Table S1). Of 115 RNAs
downregulated by ET-1, the downregulation of 69 was signifi-
cantly inhibited by PD184352 (Fig. 3B, Table S2). PD184352 had
minor effects on baseline RNA expression with few significantly
upregulated or downregulated by PD184352 alone or (despite a
negligible effect of ET-1 alone) together with ET-1 (28
upregulated; 38 downregulated) (Fig. 3, C and D; Table S3).
Thus, ERK1/2 signaling positively regulates ,65% of the IEG
response to ET-1 with a small (,2%) negative effect, and plays a
minor role in regulating baseline gene expression. For C3T, the
patterns were markedly different. Of the RNAs upregulated by
ET-1, most were unaffected by C3T (198), 18 were significantly
inhibited to a minor degree (20.1% average inhibition) and the
upregulation of 57 RNAs was significantly enhanced (Fig. 4A,
Table S4). Of RNAs downregulated by ET-1, the response for 26
was significantly inhibited (Fig. 4B, Table S5). C3T profoundly
affected baseline RNA expression alone (74 upregulated; 65
downregulated) or, despite a negligible effect of ET-1 alone,
together with ET-1 (148 upregulated; 161 downregulated) (Fig. 4,
C and D, Table S6). Thus, RhoA signaling positively regulates
,10% of the IEG response to ET-1 with negative regulation of
,14% of the response. However, it appears to have a significant
role in regulating baseline gene expression.
The microarray data were validated by qPCR. We selected ET-
1 responsive mRNAs that were inhibited by either PD184352 or
C3T (Fig. 5A), inhibited by PD184352 alone (Fig. 5B), enhanced
by C3T but inhibited by PD184352 (Fig. 5C) or with minimal
sensitivity to either inhibitor (Fig. 5D). We focused mainly on
mRNAs encoding TFs (Abra, Srf, Egr1, Egr2, Egr3, Egr4, Klf15,
Klf4 and Klf6) and receptor ligands (Areg, Bmp2, Ereg, Hbegf,
IL6, Inhba), including Slc25a25 as an additional transcript with
low sensitivity to PD184352 or C3T. Absolute relative changes
differ with the two techniques [10] but, qualitatively, the qPCR
data showed a high degree of correlation with the microarray
results (Fig. 6). The data illustrate potential autocrine/paracrine
and transcriptional networks operating downstream from the
initial stimulus, ET-1 (Fig. 7).
Cardiomyocyte RNA Expression
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10027Figure 1. Inhibition of ERK1/2 activation by PD184352. Cardiomyocytes were unstimulated (Control) or exposed to 100 nM ET-1, 2 mM
PD184352 or ET-1 in the presence of PD184352. Incubation times with ET-1 were 5 min (for activation of ERK1/2 or p38-MAPK), 15 min (for activation
of JNKs) or 1 h (for effects on effects on morphology). A, Phosphorylated (upper panel) or total (center panel) ERK1/2 were assessed by Western
blotting. Densitometric analysis is shown in the lower panel as means 6 SEM (n=5 independent experiments). * p,0.001 relative to control, #
p,0.001 relative to ET-1 alone (one-way ANOVA with Newman-Keuls post-test). B, Phosphorylated or total p38-MAPKs (upper blots) or JNKs (lower
blots) were assessed by Western blotting. The experiment was repeated with similar results. C, Cardiomyocytes were immunostained with antibodies
to troponin T. The experiment was repeated with similar results. Bar=10 mm.
doi:10.1371/journal.pone.0010027.g001
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PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10027Figure 2. Inhibition of RhoA activation by C3T. Cardiomyocytes were unstimulated (Control) or exposed to 100 nM ET-1, 1 or 5 mg/ml C3T (2 h
pretreatment) or ET-1 in the presence of C3T. Incubation times with ET-1 were 30 s (for activation of RhoA), 5 min (for activation of ERK1/2 or p38-
MAPK), 15 min (for activation of JNKs) or 1 h (for effects on morphology). A, Affinity purified RhoA.GTP (upper panel) and total RhoA (center panel)
were assessed by Western blotting. Blots are representative of 4 independent experiments. Densitometric analysis is provided in the lower panels.
Results are means 6 SEM (n=4). * p,0.001 relative to controls, # p,0.001 relative to ET-1 alone (one way ANOVA with Newman-Keuls post-test). B,
Phosphorylated or total ERK1/2 (upper blots), p38-MAPKs (center blots) or JNKs (lower blots) were assessed by Western blotting. The experiment was
repeated with similar results. C, Cardiomyocytes were exposed to ET-1 for the times indicated with or without pretreatment with C3T. Affinity purified
RhoB.GTP (upper image) and RhoC.GTP (lower image) were assessed by Western blotting. The experiment was repeated with similar results. D,
Cardiomyocytes were immunostained with antibodies to troponin T. The experiment was repeated with similar results. Bar=10 mm.
doi:10.1371/journal.pone.0010027.g002
Cardiomyocyte RNA Expression
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10027Figure 3. Regulation of cardiomyocyte RNA expression through the ERK1/2 cascade. Cardiomyocytes were unstimulated (Control) or
exposed to ET-1, PD184352 (PD) or ET-1 together with PD184352 (PD/ET-1). Changes in RNA expression were determined using microarrays using
GeneSpring analysis to identify transcripts with significant changes in expression (.1.5-fold) with or without a significant effect of the inhibitor (one-
way ANOVA with Newman-Keuls post-test and Benjamini-Hochberg false discovery rate correction). A, Upregulated by ET-1 with no effect (Group I),
inhibition (Group IIa) or enhancement by PD184352 (Group IIb). B, Downregulated by ET-1 with no effect (Group III) or inhibition by PD184352 (Group
IV). C, Upregulation (Group Va) or downregulation (Group Vb) by PD184352. D, Upregulation (Group VIa) or downregulation (Group VIb) by PD/ET-1.
Heatmaps represent all probesets in each group [Log2 scale; -2.5 (cyan) through 0 (black) to 2.5 (red)]. Histograms are means 6 SEM (numbers of
transcripts in parentheses). Statistical analysis of each group was performed using GraphPad Prism 4: * p,0.001, **p,0.05 relative to Control;
# p,0.001, relative to ET-1 alone (one-way ANOVA with Newman-Keuls post-test).
doi:10.1371/journal.pone.0010027.g003
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10027Figure 4. Regulation of cardiomyocyte RNA expression through RhoA. Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T
or ET-1 together with C3T (C3T/ET-1). Changes in RNA expression were determined using microarrays using GeneSpring analysis to identify transcripts
with significant changes in expression (.1.5-fold) with or without a significant effect of the inhibitor (one-way ANOVA with Newman-Keuls post-test
and Benjamini-Hochberg false discovery rate correction). A, Upregulated by ET-1 with no effect (Group I), inhibition (Group IIa) or enhancement by
C3T (Group IIb). B, Downregulated by ET-1 with no effect (Group III) or inhibition by C3T (Group IV). C, Upregulation (Group Va) or downregulation
(Group Vb) by C3T. D, Upregulation (Group VIa) or downregulation (Group VIb) by C3T/ET-1. Heatmaps are shown for probesets in each group [Log2
Cardiomyocyte RNA Expression
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Cardiac hypertrophy is a multifaceted, complex disorder where
various stimuli and signals conspire to initiate and propagate
disease development. This is presumably reflected at the
cardiomyocyte level, and a catalog of potential components of
the hypertrophic response has developed [6]. Confusingly, almost
all stimuli and signaling pathways are implicated in various aspects
of hypertrophy. The challenge is to integrate this information and
identify the key nodes. Here, we used highly selective inhibitors
(PD184352 and C3T) to establish the global roles of ERK1/2 vs
RhoA in regulating cardiomyocyte RNA expression. We identified
ERK1/2 as a significant node in the IEG response to ET-1,
particularly with respect to positive regulation of RNA expression,
whereas RhoA has a less significant role with positive and negative
effects (Figs. 3 and 4). As might be expected, some RNAs were not
significantly regulated by either ERK1/2 or RhoA (Fig. 5D),
implicating additional pathways in the cardiomyocyte IEG
response to ET-1. These may include other MAPKs (JNKs and
p38-MAPKs) that are activated by ET-1 [7]. p38-MAPK is
implicated in regulating mRNA stability through Zfp36 [14], a
protein which is expressed in cardiomyocytes and upregulated by
ET-1 [10], and further studies are required to assess the
importance of a p38-MAPK-Zfp36 signal in our system. Our
conclusions are summarized in Fig. 7.
Our data with PD184352 are consistent with other studies also
identifying ERK1/2 as a key node in the early response to growth
stimuli, platelet-derived growth factor and Egf [15,16]. However,
other studies have suggested that RhoA plays a more positive role
in regulating RNA expression of, for example Klf2 [17] CTGF
[18], Bax [19] or Cyr61 [20]. Although Klf2, CTGF, and Cyr61
(but not Bax) were upregulated by ET-1, this was not inhibited by
C3T and C3T alone did not influence Bax expression (Fig. 4,
Tables S4 and S6). The reasons may reflect the methods used,
times studied, stimulus and/or specific cell types. Some studies
emphasise the use of hydroxymethylglutaryl CoA reductase
inhibitors (‘‘statins’’) as inhibitors of Rho-family signaling but
these inhibitors have a range of effects apart from inhibition of
RhoA signaling [21]. Notably, we selected the minimum time and
concentration of a cell-permeable form of C3T to inhibit RhoA.
Other studies used higher concentrations with prolonged incuba-
tion that may have secondary effects. Interestingly, ERK1/2 and
RhoA converged to increase expression of Abra and Srf mRNAs
(Fig. 5A). RhoA signaling may therefore be of greater significance
in positively regulating RNA expression over longer times.
One dimension that can confer additional structure to the
system is time, and the timing/duration of signaling and gene
expression responses is likely to influence the cellular response.
Thus, a single stimulus (e.g. ET-1) may initiate hypertrophy but,
since signaling and gene expression responses are rapid and
transient, other factors, acting at later times may be required for a
fully developed response. In addition to influencing TF expression,
ET-1 and other stimuli modulate expression of a range of
paracrine/autocrine factors including Egf receptor ligands (e.g.
amphiregulin, Areg; epiregulin, Ereg, HbEGF [22]), gp130 ligands
(e.g. interleukin 6, IL6; leukemia inhibitory factor, Lif [23]) and
ligands of the transforming growth factor (Tgf) b family (e.g.
inhibin bA, Inhba; bone morphogenetic protein 2, Bmp2; Tgfb3
[24]) (Fig. 5, Table S1) each of which triggers specific receptor
subtypes to activate specific intracellular signaling pathways.
These, together with major changes in TF expression (e.g. Srf,
Egr family, Klf family TFs; Fig. 5) are likely to propagate the
response. With a likely scenario in vivo being low-level exposure to
various stimuli, we suggest that such networks facilitate progression
from a multiplicity of initiation points to a similar end-stage
hypertrophic phenotype. Understanding these networks and the
links between stimuli, signaling, TFs and gene expression is a
systems biology challenge for the future.
Materials and Methods
Ethics statement
Sprague-Dawley female rats with 2–4 day litters were purchased
from Harlan SeraLab Ltd. UK and were housed overnight in the
Imperial College Central Biomedical Services facility with water
and food ad libitum. Both facilities are UK registered with Home
Office certificates of designation. All procedures in these facilities
were performed in accordance with UK regulations and the
European Community Directive 86/609/EEC for animal exper-
iments. Animals were culled by schedule 1 (cervical dislocation) for
which additional approval and licences are not required according
to UK regulations.
Cardiomyocyte cultures
Ventricles were dissected from neonatal (1–2 d) Sprague-
Dawley rat hearts and dissociated by serial digestion with 0.4 mg/
ml collagenase and 0.6 mg/ml pancreatin sterile digestion buffer
(116 mM NaCl, 20 mM HEPES, 0.8 mM Na2HPO4, 5.6 mM
glucose, 5.4 mM KCl and 0.8 mM MgSO4, pH 7.35). The first
digestion supernatant (5 min, 37uC, 160 cycles/min in a shaking
waterbath) was removed and discarded. Cell suspensions from
subsequent digestions (20 min, 2625 min, 20 min, 10 min; 37uC
136 cycles/min shaking) were recovered by centrifugation (5 min,
606g) and the cell pellet resuspended in plating medium
(Dulbecco’s modified Eagle’s medium (DMEM)/medium 199
[4:1 (v/v)], 15% (v/v) FCS, 100 units/ml penicillin and strepto-
mycin). The cells were pre-plated on plastic tissue culture dishes
(30 min) to remove non-cardiomyocytes. For biochemistry and
molecular biology experiments, non-adherent viable cardiomyo-
cytes were plated at a density of 4610
6 cells/dish on 60 mm
Primaria dishes pre-coated with sterile 1% (w/v) gelatin (Sigma-
Aldrich UK). After 18 h myocytes were confluent and beating
spontaneously. For immunostaining experiments, cardiomyocytes
were plated at 1.5610
6 cells/dish on 35 mm Primaria dishes
containing glass coverslips pre-coated with sterile 1% (w/v) gelatin
followed by laminin (20 mg/ml in PBS; Sigma-Aldrich UK). The
plating medium was withdrawn and cells were incubated in serum-
free maintenance medium (DMEM/medium [4:1 (v/v)],
100 units/ml penicillin and streptomycin) for a further 24 h.
Cardiomyocytes were unstimulated (Controls), exposed to
PD184352 (2 mM), a cell-permeable form of the exoenzyme C3
transferase from Clostridium botulinum (C3T; 1 or 5 mg/ml) or ET-1
(100 nM), or exposed to ET-1 following pretreatment with
PD184352 (10 min) or C3T (120 min). PD184352 (Alexis
Biochemicals, Enzo Life Sciences) was prepared as a stock solution
in DMSO (4 mM). Cell-permeable C3T (Cytoskeleton Inc., Cat.
no. CT03) was resuspended in 66% (v/v) glycerol (0.02 mg/ml).
This represents highly purified C3T linked to a cell penetrating
scale; -2.5 (cyan) through 0 (black) to 2.5 (red)]. Histograms are means 6 SEM (numbers of transcripts in parentheses). Statistical analysis of each
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In the cytoplasm, the disulfide bond is reduced and the C3T
diffuses through the cell. ET-1 (Bachem UK) was prepared as a
stock solution in water (0.1 mM). ET-1, PD184352 or C3T were
added directly to the tissue culture medium. Unless otherwise
stated, incubation times with ET-1 were dependent upon the time
at which individual signaling components are substantially
activated: 30 s for RhoA.GTP loading [25], 5 min for activation
of ERK1/2 [26] or p38-MAPKs [27], 15 min for activation of
JNKs [28] and 1 h for expression of immediate early genes [10].
For inhibitor studies, cells were pre-treated with inhibitor for a
minimum period required to provide adequate inhibition of the
Figure 5. Validation of microarray data. Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, PD184352 or ET-1 together with
C3T (C3T/ET-1) or PD184352 (PD/ET-1). ET-1 responsive mRNA expression was measured by qPCR. A, mRNAs inhibited by either C3T or PD184352. B,
mRNAs inhibited by PD184352. C, mRNAs enhanced by C3T but inhibited by PD184352. D, mRNAs insensitive to either drug. Results (relative to
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ET-1 for the appropriate times. Cells were also exposed to
inhibitor alone for the full duration of the incubation time. All
samples were harvested together at the end of the experiment.
Assays for activated RhoA/B/C.GTP and phosphorylated
MAPKs
For the study of RhoA/B/C GTP-loading, a GST-fusion
protein was prepared containing residues 7–89 of murine rhotekin
(GST-RBD) [25]. Cardiomyocytes were washed with ice-cold PBS
and scraped into Buffer A [20 mM Tris-HCl (pH 7.4), 2 mM
EDTA, 100 mM KCl, 5 mM MgCl2, 5 mM NaF, 0.2 mM
Na3VO4, 0.002 mM microcystin, 10% (v/v) glycerol, 1% (v/v)
Triton X-100, 0.5% (v/v) 2-mercaptoethanol, 10 mM benzami-
dine, 0.2 mM leupeptin, 0.01 mM trans-epoxy succinyl-l-leucyla-
mido-(4-guanidino)butane, 0.3 mM phenylmethylsulfonyl fluo-
ride]. Lysates were centrifuged (10,0006g, 5 min, 4uC). A
sample of the supernatant was taken to assess total levels of
RhoA/B/C (input). Remaining extracts were incubated with
mixing (4uC, 24 h) with GST-RBD that had been previously
bound to glutathione-Sepharose beads resuspended in Buffer A.
Beads were washed with Buffer A and boiled with SDS-
polyacrylamide gel electrophoresis sample buffer (0.33 M Tris-
Figure 6. Comparison of qPCR and microarray data. Cardiomyocytes were unstimulated (Control) or exposed to ET-1, C3T, PD184352 or ET-1
together with C3T (C3T/ET-1) or PD184352 (PD/ET-1). ET-1 responsive mRNA expression measured by qPCR (see Figure 5 for detailed representations)
was compared with the microarray data (solid bars=qPCR; open bars=microarray data). Results are relative to controls and are means 6 SEM (n=4
or 5). The linear regression coefficient is provided (r) for qPCR vs microarray data.
doi:10.1371/journal.pone.0010027.g006
Cardiomyocyte RNA Expression
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dithiothreitol, 0.2 mg/mL bromphenol blue). The input and
eluted proteins were analyzed by Western blotting using 12% (w/
v) polyacrylamide gels.
For analysis of phosphorylated MAPKs, cardiomyocytes were
washed with ice-cold PBS and scraped into 150 ml buffer B
[20 mM b-glycerophosphate (pH 7.5), 50 mM NaF, 2 mM
EDTA, 0.004 mM microcystin LR, 1% (v/v) Triton X-100,
5 mM dithiothreitol, 10 mM benzamidine, 0.2 mM leupeptin,
0.01 mM trans-epoxy succinyl-l-leucylamido-(4-guanidino)butane,
0.3 mM phenylmethylsulfonyl fluoride]. Extracts were centrifuged
(5 min, 10,0006g, 4uC), the supernatants were removed, and
150 ml was boiled with 50 ml sample buffer. Total and phosphor-
ylated MAPKs were analyzed by Western blotting using 10% (w/
v) polyacrylamide gels.
Western blotting
Proteins were separated by SDS-polyacrylamide gel electro-
phoresis on 10% or 12% (w/v) polyacrylamide gels and
transferred electrophoretically to nitrocellulose. Nonspecific bind-
ing sites were blocked with 5% (w/v) nonfat milk powder in
20 mM Tris-HCl pH 7.5, 137 mM NaCl, 0.1% (v/v) Tween 20
(TBST) for 30 min. Blots were incubated with primary antibodies
(1:1000 dilution in TBST containing 5% (w/v) bovine serum
albumin, overnight, 4uC). Mouse monoclonal antibodies to RhoA
(sc-418), RhoB (sc-8048) and RhoC (sc-12116) were from Santa
Cruz Biotechnology Inc. Rabbit antibodies to dually-phosphory-
lated ERK1/2 (Cat. no. 4377), total ERK1/2 (Cat. no. 9102),
dually-phosphorylated p38-MAPKs (Cat. no. 9216), total p38-
MAPKs (Cat. no. 9212), dually-phosphorylated JNKs (Cat.
no. 4671) and total JNKs (Cat. no. 9252) were from Cell
Signaling. All antibodies were used at 1/1000 dilution. The blots
were washed with TBST (three times for 5 min, room tempera-
ture), incubated with polyclonal secondary antibodies conjugated
to horseradish peroxidase (Dako; 1:5000 dilution in TBST
containing 1% (w/v) nonfat milk powder, 1 h, room temperature)
and then washed again in TBST (three times for 5 min, room
temperature). Bands were detected by enhanced chemilumines-
cence using ECL Plus Western Blotting detection reagents (GE
Healthcare) with visualisation using an ImageQuant 350 digital
imager (GE Healthcare). ImageQuant 7.0 software (GE Health-
care) was used for densitometric analysis of the bands.
Immunostaining
Cells were washed with ice-cold PBS and fixed in 3.7% (v/v)
formaldehyde in PBS (10 min, room temperature). Cardiomyo-
cytes were permeabilised with 0.1% (v/v) Triton X-100 (10 min,
room temperature) in PBS and non-specific binding blocked with
1% (w/v) bovine serum albumin in PBS containing 0.1% (v/v)
Triton X-100 (10 min, room temperature). All incubations were at
37uC in a humidified chamber, and coverslips were washed three
times in PBS after each stage of the immunostaining procedure.
Cardiomyocytes were stained with mouse monoclonal primary
antibodies to troponin T (1/40, 60 min; Stratech Scientific, Cat.
no. MS-295-P1) with anti-mouse immunoglobulin secondary
antibodies coupled to Alexa-Fluor 488 (1/200, 60 min; Invitro-
gen). Coverslips were mounted using fluorescence mounting
medium (Dako) and viewed with a Zeiss Axioskop fluorescence
microscope using a 1006oil-immersion objective. Digital images
captured using a Canon PowerShot G3 camera were converted to
grayscale and reduced in size using Adobe Photoshop 7.0.
RNA preparation and microarray analysis
Cardiomyocytes were unstimulated (Controls, 2 per prepara-
tion), exposed to ET-1 (1 h), PD184352 (70 min) or C3T (3 h), or
exposed to ET-1 (1 h) following pretreatment with PD184352
(10 min) or C3T (2 h). Total RNA was extracted using RNA Bee
(1 ml per 4610
6 cells, AMS Biotechnology Ltd) according to the
manufacturer’s instructions. The purity was assessed from the
A260/A280 (values of 1.9–2.1 were considered acceptable). RNA
Figure 7. Schematic of signaling and gene expression responses to ET-1 in cardiomyocytes. Agonists (e.g. ET-1) activate intracellular
signaling pathways including small G proteins and protein kinases. C3T and PD184352 inhibit activation of RhoA and ERK1/2, respectively.
Intracellular signaling pathways modulate expression of immediate early genes (IEGs) including Abra/Srf that participate in RhoA-mediated regulation
of cardiomyocyte hypertrophy. These and other transcription factors (TFs) promote expression of downstream genes. Agonists are also produced that
act in autocrine/paracrine loops to initiate further cycles of signaling/gene expression. These networks eventually culminate in hypertrophy.
doi:10.1371/journal.pone.0010027.g007
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variation resulting from different cardiomyocyte preparations,
equal amounts of RNA from three individual experiments were
pooled to generate a single sample set. First-strand cDNA synthesis
was performed using 10 mg total RNA with a T7-(dT)24 primer
and Superscript II (Invitrogen) (37uC, 1 h). Second-strand cDNA
synthesis was carried out using E. coli DNA ligase, E. coli DNA
polymerase I, and RNase H (Invitrogen) (2 h, 16uC). Biotin-
labeled antisense cRNA was synthesized from purified double-
stranded cDNA using the BioArray High Yield RNA transcript
labelling kit (Enzo Diagnostics) according to the manufacturer’s
instructions. Four sets of pooled samples were prepared for
hybridization to separate Affymetrix rat genome 230 2.0 arrays
(i.e. four separate sets of samples were analysed for each condition,
prepared from a total of 12 myocyte preparations). Two separate
unstimulated controls were prepared and hybridized simulta-
neously with each set of samples. Fragmentation of antisense
cRNA and hybridization to Affymetrix rat genome 230 2.0 arrays
was performed at the CSC/IC Microarray Centre according to
the manufacturer’s instructions. MIAME-compliant data were
exported to ArrayExpress (ArrayExpress ID: E-MEXP-1977 and
E-MEXP-2516).
Data (.CEL files) were imported into GeneSpring 10.0.2
(Agilent Technologies) and were normalized using the MAS5
algorithm. Normalisation per gene was to the two corresponding
controls within each sample set. Probesets were selected for
analysis if present or marginal in all controls or all of any of the
treatments, and filtered according to fold change (.1.5-fold) with
any condition (ET-1, C3T, PD184352, C3T/ET-1 or PD184352/
ET-1) relative to controls. Probesets with statistically significant
changes (false discovery rate, FDR,0.05) were identified by one-
way ANOVA with Student-Newman-Keuls (SNK) post test,
applying a Benjamini and Hochberg multiple testing correction.
Supervised clustering was performed. RNAs were clustered
according to .1.5-fold change with ET-1 (Group A), .1.5-fold
change with PD184352 or PD184352/ET-1 (Group B), .1.5-fold
change with C3T or C3T/ET-1 (Group C). Group A was
clustered according to upregulation or downregulation with ET-1
and significant difference (inhibition or enhancement) for ET-1 vs
PD184352/ET-1 or C3T/ET-1. Groups B and C were clustered
according to upregulation or downregulation with inhibitor alone
or inhibitor plus ET-1. Gene identities for all selected probesets
were confirmed by BLAST search of probeset sequences using
the Entrez nucleotide database (www.ncbi.nlm.nih.gov/BLAST).
Further BLAST searches for unassigned sequences were per-
formed against the rat genome (www.ncbi.nlm.nih.gov/genome/
seq/BlastGen/BlastGen.cgi?taxid=10116) and the mouse ge-
nome (www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.
cgi?taxid=10090; cross-species megaBLAST) (since the rat genome
is less well annotated). Genes were classified as far as possible using
GeneOntology classifications associated with rat, mouse and
human orthologs (NCBI Entrez Gene; www.ncbi.nlm.nih.gov/
entrez), taking into account both probable Function and Process.
For genes with conflicting potential functions, further searches
were performed using PubMed (www.ncbi.nlm.nih.gov/sites/
entrez?db=pubmed) to ascertain probable biochemical function.
Validation of microarray results by qPCR
Cardiomyocytes were treated and total RNA extracted as for
microarray analysis. cDNAs were synthesized using High Capacity
cDNA Reverse Transcription Kits with random primers (Applied
Biosystems) according to the manufacturer’s instructions. For
selected genes, gene sequences were obtained from NCBI Entrez
Gene and information on gene structures was obtained from
Ensembl (www.emsembl.org). Primers were designed for qPCR
with an amplicon size of 50-150 bp, within 1000 bp of the 39 end
of the mRNA and, where possible, across an exon boundary
(Table S7). qPCR was performed using an ABI Real-Time PCR
7500 system (Applied Biosystems). Optical 96-well reaction plates
were used containing (in each well) 12.5 ml SYBR Green Jump
Start Taq Readymix (Sigma-Aldrich UK), 5 ml oligonucleotide
primers (5 pmol each of forward and reverse primers) and 7.5 ml
(1 mg) cDNA template. qPCR was performed using absolute
quantification with the standard curve protocol. Dissociation curve
analysis was routinely performed to identify any aberrant
amplification products. Values for selected RNAs were normalized
to glyceraldehyde 3-phosphate dehydrogenase (Gapdh) expression
and then to control values.
Supporting Information
Table S1 RNAs upregulated in cardiomyocytes by ET-1: effects
of PD184352. Cardiomyocytes were unstimulated (Control) or
exposed to ET-1, PD184352 (PD) or ET-1 in the presence of
PD184352 (PD/ET-1). Microarray analysis was performed to
identify RNAs significantly upregulated by ET-1 (.1.5-fold
change, FDR,0.05) and with significant inhibition or enhance-
ment with PD184352. Raw values are provided for Controls and
expression relative to Controls is provided for PD, ET-1 and PD/
ET-1. Results are means for 4 separate hybridisations. Where
multiple probesets represented the same RNA, individual raw
values are provided for controls and, since the relative fold changes
were similar, the mean values are provided for the treatments.
RNAs in each group (inhibited by PD184352, enhanced by
PD184352, no significant effect of PD184352) are listed alpha-
betically according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s001 (0.51 MB
DOC)
Table S2 RNAs downregulated in cardiomyocytes by ET-1:
effects of PD184352. Cardiomyocytes were unstimulated (Control)
or exposed to ET-1, PD184352 (PD) or ET-1 in the presence of
PD184352 (PD/ET-1). Microarray analysis was performed to
identify RNAs significantly downregulated by ET-1 (.1.5-fold
change, FDR,0.05) and with significant inhibition or enhance-
ment with PD184352. Raw values are provided for Controls and
expression relative to Controls is provided for PD, ET-1 and PD/
ET-1. Results are means for 4 separate hybridisations. Where
multiple probesets represented the same RNA, individual raw
values are provided for controls and, since the relative fold changes
were similar, the mean values are provided for the treatments.
RNAs in each group (inhibited by PD184352, no significant effect
of PD184352) are listed alphabetically according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s002 (0.23 MB
DOC)
Table S3 RNAs regulated in cardiomyocytes by PD184352
alone or PD184352 in the presence of ET-1. Cardiomyocytes were
unstimulated (Control) or exposed to ET-1, PD184352 (PD) or
ET-1 in the presence of PD184352 (PD/ET-1). Microarray
analysis was performed. RNAs not significantly regulated by ET-1
alone but significantly regulated by PD or PD/ET-1 were selected
(.1.5-fold change, FDR,0.05) and clustered according to
upregulation or downregulation. Raw values are provided for
Controls and expression relative to Controls is provided for PD,
ET-1 and PD/ET-1. Results are means for 4 separate hybridisa-
tions. Where multiple probesets represented the same RNA,
individual raw values are provided for controls and, since the
relative fold changes were similar, the mean values are provided
Cardiomyocyte RNA Expression
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according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s003 (0.15 MB
DOC)
Table S4 RNAs upregulated in cardiomyocytes by ET-1: effects
of C3T. Cardiomyocytes were unstimulated (Control) or exposed
to ET-1, C3T or ET-1 in the presence of C3T (C3T/ET-1).
Microarray analysis was performed to identify RNAs significantly
upregulated by ET-1 (.1.5-fold change, FDR,0.05) and with
significant inhibition or enhancement with C3T. Raw values are
provided for Controls and expression relative to Controls is
provided for C3T, ET-1 and C3T/ET-1. Results are means for 4
separate hybridisations. Where multiple probesets represented the
same RNA, individual raw values are provided for controls and,
since the relative fold changes were similar, the mean values are
provided for the treatments. RNAs in each group (inhibited by
C3T, enhanced by C3T, no significant effect of C3T) are listed
alphabetically according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s004 (0.50 MB
DOC)
Table S5 RNAs upregulated in cardiomyocytes by ET-1: effects
of C3T. Cardiomyocytes were unstimulated (Control) or exposed
to ET-1, C3T or ET-1 in the presence of C3T (C3T/ET-1).
Microarray analysis was performed to identify RNAs significantly
downregulated by ET-1 (.1.5-fold change, FDR,0.05) and with
significant inhibition or enhancement with C3T. Raw values are
provided for Controls and expression relative to Controls is
provided for C3T, ET-1 and C3T/ET-1. Results are means for 4
separate hybridisations. Where multiple probesets represented the
same RNA, individual raw values are provided for controls and,
since the relative fold changes were similar, the mean values are
provided for the treatments. RNAs in each group (inhibited by
C3T, no significant effect of C3T) are listed alphabetically
according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s005 (0.23 MB
DOC)
Table S6 RNAs regulated in cardiomyocytes by C3T alone or
C3T in the presence of ET-1. Cardiomyocytes were unstimulated
(Control) or exposed to ET-1, C3T or ET-1 in the presence of
C3T (C3T/ET-1). Microarray analysis was performed. RNAs not
significantly regulated by ET-1 alone but significantly regulated by
C3T or C3T/ET-1 were selected (.1.5-fold change, FDR,0.05)
and clustered according to upregulation or downregulation. Raw
values are provided for Controls and expression relative to
Controls is provided for C3T, ET-1 and C3T/ET-1. Results are
means for 4 separate hybridisations. Where multiple probesets
represented the same RNA, individual raw values are provided for
controls and, since the relative fold changes were similar, the mean
values are provided for the treatments. RNAs in each group are
listed alphabetically according to gene symbol.
Found at: doi:10.1371/journal.pone.0010027.s006 (0.84 MB
DOC)
Table S7 Primers used for qPCR validation of microarray data.
Nucleotide positions in transcripts are shown in parentheses for
each primer. mRNA sequences (accession numbers provided) for
established genes were obtained from the Rat Genome Database
(http://rgb.mcw.edu, viewed at http://www.ncbi.nlm.nih.gov/
entrez).
Found at: doi:10.1371/journal.pone.0010027.s007 (0.01 MB
PDF)
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